Axelar is developing anti-cancer treatments that target the insulin-like growth factor-1 receptor signaling pathway.

The company’s lead drug candidate, AXL1717, is an orally bioavailable small molecule with dual mechanisms of action. AXL1717 targets the IGF-1R signaling pathway but does not bind the IGF-1R. It reduces the level of non-phosphorylated and phosphorylated IGF-1R. AXL1717 has also been shown to yield cell cycle arrest in mitosis, due to indirect effects on microtubule dynamics, making it a unique anti-cancer drug.

Building on extraordinary efficacy results in animal studies and a successful Phase I/II program, Axelar has now completed a randomized, controlled, multicenter, multinational Phase II study on non-small cell lung cancer.

Axelar aims to partner with a pharmaceutical company to complete the clinical program and bring a product to market.